Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Feb 5;75(1):226–228. doi: 10.1016/j.jhep.2021.01.036

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Associations between age and comorbidity with death following SARS-CoV-2 infection in liver transplant patients.

(A) Outcomes of multivariable logistic regression with backwards stepwise selection for retention in the model at p <0.1 with death as the dependent variable and the following independent variables: age, sex, Charlson comorbidity index (CCI; without age), hypertension, and baseline tacrolimus, ciclosporin, mycophenolate mofetil (MMF), everolimus, and corticosteroid use. SETH = cohort described by Colmenero et al; CH/SC = COVID-Hep/SECURE-Cirrhosis; combined represents the 2 cohorts combined. Within the SETH cohort, factors remaining significantly associated with death were age (odds ratio [OR] 3.47/10 years; 95% CI 1.50–8.00; p = 0.004) and CCI without age (1.29/point; 95% CI 1.00–1.67; p = 0.049). Within the COVID-Hep/SECURE-Cirrhosis cohort only age (OR 1.73/10 years; 95% CI 1.09–2.74; p = 0.02) remained significant. Within the combined cohort, age (1.95/10 years; 1.35–2.82; p <0.001) and CCI (OR 1.24; 95% CI 1.04–1.48; p = 0.014) remained significant. (B–D) Plots of age in years against CCI adjusted to exclude age and split by whether patients survived (blue circles) or died (red squares) following SARS-CoV-2 infection in (B) Spanish SETH cohort (n = 108 with complete data); (C) COVID-Hep/SECURE-Cirrhosis international cohort (n = 150); (D) COVID-Hep/SECURE-Cirrhosis comparison non-LT cohort from a single UK hospital network (n = 627). A single Spanish patient from the COVID-Hep/SECURE-Cirrhosis registries who could potentially have been included in the Spanish SETH registry was not included in the analysis. Asterisks for patients who died with CCI <3 (including points for age) in panel B denote additional at-risk cofactors: ∗concurrent influenza; ∗∗second liver transplant; ∗∗∗recurrent primary sclerosing cholangitis with jaundice at baseline; ∗∗∗∗baseline jaundice of unknown cause. Horizontal jitter has been added to the X axis. (This figure appears in color on the web.)